Preclinical in vivo work has shown that deletion of IGFBP-I in the c-Myc transgenic mouse model resulted in decreased proliferation of prostatic tissue but had no effect on the development of prostate cancer [33]. The gene discussed is MYC; the disease is prostate carcinoma.